Een dosisvariërend onderzoek om Testagen® TDS-testosteron 5% te onderzoeken (PARC-T-D)
Een meervoudige dosis, enkele periode, fase II-dosisvariërend onderzoek om Testagen® TDS-testosteron 5% te onderzoeken bij volwassen mannelijke proefpersonen
This study is a continuation of previous studies done in healthy volunteers to prove the efficacy of delivering Testosterone, the male hormone, rapidly across intact skin in s series of doses from low to high in men with low-to-no natural testosterone production to measure their response to the varying doses. The results of this study will inform further studies which will be longer in length, as to the starting doses. The study will be conducted in London, U.K. at the Advanced Therapies Centre, The London Clinic.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
48 Patients will be enrolled following 2 independent verifying blood tests of their diagnosis of Hypogonadism. there will be 4 cohorts of 12 subjects, each receiving doses of the trail materials, titrated by means of number of sprays applied. Doses will range from 10 to 70 mgs Testosterone.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 2
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Shern L. Chew, M.D., Ph.D.
- Telefoonnummer: 011-44-20 034 6227
- E-mail: sl.chew@thelondonclinic.co.uk
Studie Contact Back-up
- Naam: Chandan AS Alam, MD
- Telefoonnummer: 011-44-7785-717596
- E-mail: calam@tdsc.us
Studie Locaties
-
-
-
London, Verenigd Koninkrijk, NW1 4LJ
- Advanced Therapies Centre, The London Clinic
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Hypogonadal Male subjects - morning testosterone level ≤300 ng/dL (10.4 ng/L).
- 18 and 75 years of age, inclusive.
- The subject is willing and able to read, understand the Subject Information Sheet and provide written informed consent.
- The subject has a body mass index (BMI) within 18-30 kg/m2.
- The subject is in otherwise good health as determined by medical history and physical examination.
- The subject is a non-smoker.
- The subject must agree to comply with the placement of an indwelling catheter on two separate occasions and the drawing of blood samples for the pharmacokinetic assessments.
- The subject is willing and able to comply with all testing and requirements defined in the protocol.
- The subject is willing and able to return to the study site for all visits.
Exclusion Criteria:
- The subject has any relevant deviations from normal in physical examination, electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the investigator, particularly an elevated PSA reading >4.0 ng/ml or ALT and AST greater than 2 times the upper limit of normal, clinically significant anemia (hematocrit <35%) or renal dysfunction (creatinine >2mg/dL), active deep vein thrombosis, thromboembolic disorders or history of these conditions.
- The subject has had a clinically significant illness within 30 days preceding entry into this study.
- The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.
- The subject has a known allergy or history of hypersensitivity to Testosterone or similar compounds.
- The subject has used any prescription medication within 14 days or over-the-counter (OTC) medication or alcohol within 48 hours of dosing or intends to use any prescription or OTC medication during the study that may interfere with the evaluation of study medication.
- The subject has donated or lost a significant volume of blood (>450 mL) within four (4) weeks of the study, and their haemoglobin concentration and haematocrit have not returned to within 5% of normal.
- The subject has a Hematocrit level > 51%
- The subject has a history of substance abuse or a current positive urine drug screen or urine alcohol test.
- Alcohol consumption greater than community norms (i.e. more than 21 standard drinks per week for males).
- Subjects who have received an investigational drug or have used an investigational device in the 30 days prior to study entry.
- Subjects with an American Urological Association System Index for Prostatism score greater than 7
- Subjects with a history of prostate or breast carcinoma.
- Subjects with prostatic mass on screening physical examination.
- Subjects with a history of significant skin disease.
- Subjects with a history of sleep apnea.
- Subject with a partner with a history of breast cancer.
- Subject with a partner of child bearing potential who is not willing to use adequate contraception for the duration of the trial.
- Subject whose partner is pregnant.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Actieve vergelijker: Forearm dose
Half of Ss will receive their dose of Testosterone on the inner aspects of their forearms. |
10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions. A dose of product solution is delivered by means of a metered pump spray. |
|
Actieve vergelijker: Chest Dose
Half of Ss will receive their dose of Testosterone on the chest. |
10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions. A dose of product solution is delivered by means of a metered pump spray. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Dose Range Measure of serum levels of testosterone in response to varying doses
Tijdsspanne: 1 week
|
A pharmacokinetic measure of serum levels of testosterone in response to varying doses of from 10 to 70 mgs of Testosterone. |
1 week
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Dermal Safety as measured by
Tijdsspanne: 1 Week
|
Incidence of treatment-emergent side effects. |
1 Week
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Shern L. Chew, M.D., Ph.D., Consultant Physician and Professor of Endocrine Medicine
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Geschat)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Endocriene systeemziekten
- Gonadale aandoeningen
- Hypogonadisme
- Hormonen
- Hormonen, hormoonvervangers en hormoonantagonisten
- Polycyclische verbindingen
- Steroïden
- Verbindingen met gefuseerde ring
- Gonadale steroïde hormonen
- Gonadale hormonen
- Androstenes
- Androstanes
- Androstenols
- Testosteron congeners
- Testosteron
Andere studie-ID-nummers
Andere studie-ID-nummers
- PARC-Testosterone-D1/09/13
- 2013-001766-42 (EudraCT-nummer)
- IRAS project ID: 146877 (Andere identificatie: NHS London - West London & GTAC Research Ethics Committee)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .